Pfizer’s Lyrica does not affect reproductive function in healthy males

Pfizer Inc. (NYSE: PFE) announced today that top-line results for Lyrica^® (pregabalin) capsules CV Study A0081104 - Assessment of the Impact of Lyrica on Sperm Production in Healthy Volunteers - demonstrate that Lyrica does not affect the reproductive function in healthy males when compared to placebo. The study was conducted as a post-approval commitment required by the US Food and Drug Administration (FDA). Pfizer will continue to further analyze the study results.